Your browser doesn't support javascript.
loading
Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling.
Kennedy, Amanda J; Ballante, Flavio; Johansson, Johan R; Milligan, Graeme; Sundström, Linda; Nordqvist, Anneli; Carlsson, Jens.
Afiliação
  • Kennedy AJ; Discovery Sciences and Cardiovascular Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden.
  • Ballante F; Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC Box 596, SE-751 24 Uppsala, Sweden.
  • Johansson JR; Discovery Sciences and Cardiovascular Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden.
  • Milligan G; Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom.
  • Sundström L; Discovery Sciences and Cardiovascular Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden.
  • Nordqvist A; Discovery Sciences and Cardiovascular Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden.
  • Carlsson J; Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC Box 596, SE-751 24 Uppsala, Sweden.
ACS Pharmacol Transl Sci ; 1(2): 119-133, 2018 Nov 09.
Article em En | MEDLINE | ID: mdl-32219208
ABSTRACT
Protease-activated receptor 2 (PAR2) is a G-protein-coupled receptor that is activated by proteolytic cleavage of its N-terminus. The unmasked N-terminal peptide then binds to the transmembrane bundle, leading to activation of intracellular signaling pathways associated with inflammation and cancer. Recently determined crystal structures have revealed binding sites of PAR2 antagonists, but the binding mode of the peptide agonist remains unknown. In order to generate a model of PAR2 in complex with peptide SLIGKV, corresponding to the trypsin-exposed tethered ligand, the orthosteric binding site was probed by iterative combinations of receptor mutagenesis, agonist ligand modifications, and data-driven structural modeling. Flexible-receptor docking identified a conserved binding mode for agonists related to the endogenous ligand that was consistent with the experimental data and allowed synthesis of a novel peptide (1-benzyl-1H[1,2,3]triazole-4-yl-LIGKV) with functional potency higher than that of SLIGKV. The final model may be used to understand the structural basis of PAR2 activation and in virtual screens to identify novel agonists and competitive antagonists. The combined experimental and computational approach to characterize agonist binding to PAR2 can be extended to study the many other G protein-coupled receptors that recognize peptides or proteins.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article